Chugai Pharmaceutical Co., Ltd. (CHGCY)

USD 21.75

(-4.1%)

Market Cap (In USD)

71.57 Billion

Revenue (In USD)

1111.36 Billion

Net Income (In USD)

325.47 Billion

Avg. Volume

74.86 Thousand

Currency
USD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
14.52-26.0
PE
-
EPS
-
Beta Value
0.497
ISIN
US1712691039
CUSIP
171269103
CIK
1453934
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Drug Manufacturers - General
CEO
Dr. Osamu Okuda
Employee Count
-
Website
https://www.chugai-pharm.co.jp
Ipo Date
2012-08-03
Details
Chugai Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, manufacturing, sale, importation, and exportation of pharmaceuticals in Japan and internationally. The company's products for oncology primarily include Avastin, Tecentriq, Perjeta, Alecensa, Herceptin, Kadcyla, Rituxan, Gazyva, and Xeloda; osteoporosis, including Actemra, Edirol, and Bonviva; renal diseases consist of Mircera and Oxarol; and neurology/other diseases comprise Hemlibra, CellCept, and Enspryng. It has various development product candidates in the areas of oncology, bone and joint diseases, autoimmune diseases, renal diseases, neurology, and other diseases. Chugai Pharmaceutical Co., Ltd. has strategic alliances with Roche Group; and collaboration and joint research with academia. The company was founded in 1925 and is headquartered in Tokyo, Japan. Chugai Pharmaceutical Co., Ltd. is a subsidiary of Roche Holding Ltd.